Muir-Torre syndrome: Case report of a patient with concurrent jejunal and ureteral cancer and a review of the literature,☆☆

https://doi.org/10.1016/S0190-9622(99)70001-0Get rights and content
Under a Creative Commons license
open archive

Abstract

Background: Muir-Torre syndrome is a rare autosomal dominant genodermatosis, first described in 1967, characterized by the presence of sebaceous tumors and an internal malignancy in the absence of other predisposing factors. Objective: Our purpose was to review and update published literature on Muir-Torre syndrome. Methods: We describe a 66-year-old white man with a history of sebaceous tumors and newly diagnosed transitional cell cancer of the right ureter and adenocarcinoma of the jejunum. The literature on Muir-Torre syndrome is reviewed by means of MEDLINE search and available published reports and updated. Results: Only 205 cases of Muir-Torre syndrome with 399 internal malignancies have been reported. The common presentation is the presence of sebaceous tumors along with a low-grade visceral malignancy. Sebaceous tumors appeared before the internal malignancy in 45 cases (22%), concurrently in 12 (6%), and after the internal malignancy in 114 (56%). In 33 (16%) of 205 patients, a temporal relationship was not reported. The total number of sebaceous gland carcinomas reported is 44; 17 of 44 were neoplasms of the meibomian gland. Keratoacanthomas have been noted in 48 (23%) of 205 patients. Gastrointestinal cancers are the most common internal malignancies (61%), followed by genitourinary (22%). Conclusion: The presence of sebaceous tumors warrants a search for an internal malignancy. In patients with Muir-Torre syndrome, regular follow-up and search for new malignancy is mandatory. Evaluation and monitoring of the family members of patients are also necessary. Patients and their families should be counseled for genetic testing. Genetic analysis of the primary tumor and skin lesions should be arranged as an added research tool if possible to better understand the disease. (J Am Acad Dermatol 1999;41:681-6.)

Cited by (0)

Reprint requests: Saad Akhtar, MD, Johns Hopkins Oncology Center, 600 N Wolfe St, Room 3-121, Baltimore, MD 21287-8985.E-mail: [email protected].

☆☆

0190-9622/99/$8.00 + 0  16/1/101088